Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)

Stanley Laman Group Ltd. increased its stake in Pfizer Inc. (NYSE:PFE) by 411.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,599 shares of the biopharmaceutical company’s stock after acquiring an additional 44,722 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Pfizer were worth $1,601,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the 3rd quarter valued at $30,000. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter valued at $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE traded up $0.12 on Friday, reaching $25.38. 46,479,102 shares of the company’s stock were exchanged, compared to its average volume of 42,011,723. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $143.72 billion, a price-to-earnings ratio of 70.50, a P/E/G ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a fifty day simple moving average of $26.96 and a 200-day simple moving average of $28.42.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the business earned $1.14 earnings per share. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.62%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.